









Markets
/
Stocks
/
nasdaq-clgn
/

Collplant Biotechnologies Ltd

CLGN



View Detailed Chart

2.515USD

-0.125-4.73%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

31.98MMarket Cap

LossP/E TTM



Collplant Biotechnologies Ltd

2.515

-0.125-4.73%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

-4.73%

5 Days

-4.01%

1 Month

+2.03%

6 Months

-18.56%

Year to Date

-30.14%

1 Year

-46.72%

View Detailed Chart

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

169 / 506

Overall Ranking

280 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.500

Target Price

+335.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 72.24% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 515.00K.

Fairly Valued

The company’s latest PE is -2.23, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 5.52M shares, increasing 3.08% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 41.60K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.72.